Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone

被引:72
作者
Gorski, JC [1 ]
Jones, DR [1 ]
Wrighton, SA [1 ]
Hall, SD [1 ]
机构
[1] ELI LILLY & CO,LILLY RES LABS,DEPT DRUG METAB & DISPOSIT,INDIANAPOLIS,IN 46285
关键词
D O I
10.1080/004982597240578
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The capability of human CYPs other than 2E1 to catalyse the formation of 6-hydroxychlorzoxazone (6OHCHZ) was examined in vitro using human liver microsomes. 2. 4-Methylpyrazole, diethyldithiocarbamate (DDC), and rabbit anti-human CYP2E1 antibodies reduced chlorzoxazone 6-hydroxylase activity by 60, 60 and 50 %, respectively. The rate of formation of 6OHCHZ by DDC-treated microsomes was reduced further by the 3A inhibitors midazolam, troleandomycin and gestodene and increased by alpha-naphthoflavone, a 3A4 stimulator. 3. Following preincubation with DDC there were significant correlations (p < 0.05) between the residual CHZ 6-hydroxylase activity and immuno-quantified CYP3A levels, and corresponding activities (e.g. midazolam 1'-hydroxylation). Rabbit anti-human CYP3A antibodies alone and in combination with DDC reduced the formation of 6OHCHZ by 47 and 62% respectively. 4. cDNA expressed CYP3A4, 2E1 and 2D6 exhibited comparable CHZ 6-hydroxylase activity. CHZ modulated 3A4 activity as reflected by midazolam 1'-hydroxylase and 4-hydroxylase activities. 5. CYP3A may make a significant contribution to CHZ 6-hydroxylation and therefore caution should be exercized when chlorzoxazone is employed as a specific 2E1 probe in vitro and in vivo.
引用
收藏
页码:243 / 256
页数:14
相关论文
共 50 条
  • [1] IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM
    ANDERSSON, T
    MINERS, JO
    VERONESE, ME
    BIRKETT, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) : 597 - 604
  • [2] IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM
    ANDERSSON, T
    MINERS, JO
    VERONESE, ME
    TASSANEEYAKUL, W
    TASSANEEYAKUL, W
    MEYER, UA
    BIRKETT, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) : 521 - 530
  • [3] [Anonymous], 1981, Statistical Tables
  • [4] INTERACTION BETWEEN 2 PROBES USED FOR PHENOTYPING CYTOCHROMES P4501A2 (CAFFEINE) AND P4502E1 (CHLORZOXAZONE) IN HUMANS
    BERTHOU, F
    GOASDUFF, T
    LUCAS, D
    DREANO, Y
    LEBOT, MH
    MENEZ, JF
    [J]. PHARMACOGENETICS, 1995, 5 (02): : 72 - 79
  • [5] BIENVENU T, 1991, INT J CLIN PHARM TH, V29, P441
  • [6] BOTH CYTOCHROMES P450 2E1 AND 1A1 ARE INVOLVED IN THE METABOLISM OF CHLORZOXAZONE
    CARRIERE, V
    GOASDUFF, T
    RATANASAVANH, D
    MOREL, F
    GAUTIER, JC
    GUILLOUZO, A
    BEAUNE, P
    BERTHOU, F
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1993, 6 (06) : 852 - 857
  • [7] EVALUATION OF TRIACETYLOLEANDOMYCIN, ALPHA-NAPHTHOFLAVONE AND DIETHYLDITHIOCARBAMATE AS SELECTIVE CHEMICAL PROBES FOR INHIBITION OF HUMAN CYTOCHROMES P450
    CHANG, TKH
    GONZALEZ, FJ
    WAXMAN, DJ
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 311 (02) : 437 - 442
  • [8] ALCOHOL METABOLISM AND TOXICITY - ROLE OF CYTOCHROME-P-450
    COON, MJ
    KOOP, DR
    REEVE, LE
    CRUMP, BL
    [J]. FUNDAMENTAL AND APPLIED TOXICOLOGY, 1984, 4 (02): : 134 - 143
  • [9] FLEMING CM, 1992, MOL PHARMACOL, V41, P975
  • [10] FUNCKBRETANO C, 1993, J PHARM EXPT THERAPE, V263, P780